Objective: The objective was to determine if ascending aorta (AscAo) diameters measured by noncontrast computed tomography (CT) allow for meaningful discrimination between patients with and without type A aortic dissection (TAAD), ideally with 100% sensitivity.
Results: A total of 230 cases of TAAD and 325 controls were included in the study. The median ages for cases and controls were 65 and 62 years, and the median AscAo diameters were 50 and 35 mm, respectively. The raw and normalized AscAo diameters demonstrated similarly excellent discrimination (AUCs of 0.96 vs. 0.97, respectively; ΔAUC = 0.01, p = 0.09) and an NRI of 0.30 (95% confidence interval [CI] = 0.13-0.47), both indicating small incremental improvements in classification with the use of the normalized AscAo measures. A raw AscAo diameter of 34 mm and a normalized Z-score of 1.84 both yielded 100% sensitivity for TAAD, with respective specificities of 35% (95% CI = 29.6%-40.2%) and 67% (95% CI = 61.7%-72.2%).
Conclusions: Nearly all patients with TAAD appear to have enlarged AscAo diameters as measured by noncontrast CT, whereas most patients with suspected but absent TAAD have relatively normal AscAo diameters. Both raw and normalized AscAo measures provided relatively comparable discriminatory value. If validated, these data may be useful in adjudicating risk among patients with suspected TAAD in whom a criterion standard test is unavailable, nondiagnostic, or contraindicated. P roximal thoracic aortic dissections (Stanford classification type A) occur with an incidence of four per 100,000 person-years and an observed average mortality of 25%. While patients with specific structural and genetic diseases are at higher risk for type A aortic dissection (TAAD), prospective registries have found that the majority of cases occur in patients without these known predispositions, but with similar resultant mortality rates. 1 Unfortunately patients with acute TAAD have highly variable clinical presentations, 2, 3 leaving clinicians to rely on gestalt and the liberal use of advanced imaging modalities, in particular high-dose computed tomography (CT) angiography, magnetic resonance imaging (MRI), and transesophageal echocardiography (TEE), all of which have reported sensitivities for TAAD around 98%. 4 Given the highly morbid consequences of misdiagnosis, very low (i.e., less than 2%) testing thresholds are commonly promoted with correspondingly low diagnostic yields. 5, 6 However, despite liberal screening recommendations, rates of initial misdiagnosis range from 14% to 31%. 7, 8 As such, TAADs represent a high-risk diagnostic clinical challenge.
Fortunately, there are anatomic factors that may reliably identify at-risk patients and direct more appropriate use of advanced imaging. Analysis of one single-center (177 patients) 9 and one multicenter registry (591 patients) 1 of patients with acute TAAD revealed that only 5% to 10% of patients in these studies had maximal ascending aorta (AscAo) diameters less than 4.0 cm. Conversely, nearly all healthy men and women have maximal AscAo diameters less than 4.0 cm (upper 95th percentiles between 3.8-4.2 and 3.4-3.9 cm, respectively). 10 Along these lines, predictive models using age, gender and body surface area (BSA) have been developed to further refine population norms for AscAo diameters. [10] [11] [12] [13] Using normalized measures based on these models might significantly improve the discriminative ability of an AscAo diameter to detect TAAD, as opposed to using a single raw threshold diameter.
We hypothesized that, among emergency department (ED) patients undergoing CT angiography to rule out TAAD, the use of AscAo measurements (as measured on noncontrast CT images) would allow for excellent discrimination between patients with and without TAAD, allowing for determination of a threshold with 100% sensitivity for TAAD as well as clinically useful specificity. We additionally hypothesized that normalization of these AscAo measurements for patient age, sex, and BSA would further improve predictive performance. Identification of such thresholds might allow for accurate TAAD risk stratification using AscAo measurements obtained by transthoracic echocardiography (TTE) or noncontrast CT, the latter being relevant for patients with contraindications to intravenous contrast or nondiagnostic CT angiography. 29 or I77.79). Charts were then manually reviewed for case status confirmation both based on CT evidence of thoracic aortic dissection using the radiologist's finalized interpretation in addition to documented clinical concern for acute thoracic aortic dissection by a consulting cardiothoracic or vascular surgeon, or in cases of death prior to consultation, based on ED physician documentation. Designation of Type A Stanford classification of the aortic dissection was based on radiologist's finalized interpretation, or if not specified therein, based on the consulting cardiothoracic or vascular surgeon's documentation.
METHODS
Control patients were electronically selected from ED patients who underwent CT angiography of the chest during an index ED visit with a reason for referral of "aneurysm/dissection" in a planned 2:1 ratio of controls to cases. Random selection of charts was performed using the RAND function in Microsoft Excel 2016 to generate a pseudo-random value for each patient, which was then used to assign a sorting order for review. Manual review of control charts and images was performed to confirm a documented complaint of chest pain and that a CT protocol for aortic dissection was performed (based on the written radiology report); patients without complaints of chest pain or with alternatively (or inadequately) protocoled CT were excluded from the study. Only the first ED encounter was included for analysis if multiple qualifying encounters were present for a given patient. In addition, controls were required to have continuously active KPNC health plan membership for the 30 days following the index ED visit, and were excluded from the control cohort if they had a subsequent diagnosis of acute aortic dissection or death in that 30-day period. Additional exclusion criteria for both cases and controls were a previous diagnosis of aortic dissection, pregnancy at the time of the index visit, presence of thoracic trauma, active incarceration, or unknown sex.
Measurements
The following variables were electronically abstracted from structured databases drawn from the electronic health record: age, sex, ethnicity, height, weight, past medical history (hypertension, diabetes, aortic stenosis), predisposing syndromes associated with TAAD (Marfan's, Turner's, fibromuscular dysplasia) and family history of aortic dissection or aneurysm. CT images were obtained using either 16-or 64-slice technology on a variety of platforms, most being performed without electrocardiogram synchronized image capture (cardiac-gating), as is commonplace under emergent diagnostic circumstances.
14 Digitized CT images (iSite PACS, Koninklijke Philips NV) from the initial diagnostic study were analyzed by two emergency physicians (DGM and JAD) to obtain manual measurements of the AscAo diameter using the precontrast series. An axial slice at the level of the mid-right pulmonary artery was selected to obtain two separate measurements of the AscAo (anterior-posterior and left-anterior oblique) using outside-to-outside wall measurements. 1, 11 The maximum diameter of these two measures was used for analysis. Measurements were rounded to the nearest millimeter. One author (JAD) analyzed all cases and a second (DGM) analyzed all controls. A subset of 70 randomly selected case CTs were reviewed independently by both authors to assess inter-rater reliability, and an additional subset of 20 randomly selected case and control CTs was analyzed twice by each respective reader in a blinded fashion to assess intra-rater reliability. Blinding to case versus control status during imaging review was not feasible, however, given that direct or indirect evidence of TAAD was frequently present on the precontrast series.
Data Analysis
Normalized values for AscAo diameter were calculated using a formula that accounts for individual patient age, sex, and BSA. 10 In brief, following logarithmic transformation of age and AscAo diameters (for homogeneity of variance), the difference between expected and observed AscAo diameters was standardized to obtain a Z-score (i.e., the number of standard deviations between the observed and expected AscAo diameters). Both the raw and the normalized AscAo diameter values (the latter in terms of the Z-score) were then modeled independently against the outcome (case status) to determine relative discrimination as well as the sensitivity and specificity of various cut points.
To assess the comparative discrimination of raw versus normalized AscAo diameters, we used receiver operating characteristic curves, reporting the Youden index, area under the receiver operating characteristic curve (AUC), and change in AUC (ΔAUC), including subgroup analyses among older (age > 65 years) and larger (BSA of 2.0 m 2 or greater) patients. We also calculated the continuous net reclassification index (NRI) as an additional measure of incremental discrimination at the individual patient level. 15 Marker calibration was assessed graphically using locally weighted scatterplot smoothed calibration curves as well as with the HosmerLemeshow test. 16 Overall marker performance was assessed using the scaled Brier score, calculated as [1 -observed Brier score/maximal possible Brier score], and expressed as a percentage which is comparable in scale and interpretation to Pearson's R 2 statistic. 17 To identify clinically useful cut points, we assessed for the maximal AscAo diameter with 100% sensitivity, as well as the cut point corresponding to the optimal overall AUC for each model (i.e., greatest summation of sensitivity and specificity, referable to the Youden index). We determined a priori that, using an optimal sensitivity point estimate of 100%, we would need 188 cases of TAAD to achieve a lower 95% confidence interval (CI) limit of 98% or greater. Inter-and intrarater agreement were assessed using Bland Altman plots, reported as absolute and proportional (to the mean) limits of agreement, as well as using intraclass correlation coefficients (two-way mixed effects, consistency, and multiple raters model). 18, 19 CIs were calculated using Clopper-Pearson exact intervals, with the exception of those for both the AUC and the NRI, which were bootstrapped from 1000 random replications maintaining the original proportionality between cases and controls. 20 P-values were calculated using chisquare and Wilcoxon signed-rank tests as indicated. All analyses were performed using Stata v.13 (StataCorp LLC, College Station, TX, USA).
RESULTS
We identified 230 cases of TAAD of 595 manually reviewed charts. An additional 325 controls were randomly selected out of a total of 14,306 potentially eligible patients, truncated at less than the planned 1:2 ratio of cases to controls due to time and budget limitations (see Data Supplement S1 [available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.com/d oi/10.1111/acem.13547/full], Figures e1 and e2) . The median age for cases and controls was 65 and 62 years, respectively, with fewer patients carrying a diagnosis of diabetes mellitus in the case group (5% vs. 26%). The median raw AscAo diameters were 50 and 35 mm, respectively. Demographic and summary findings for the case and control cohorts are presented in Table 1 . Table 2 outlines the respective performance measures between the raw and normalized AscAo values. Receiver operating curve analysis (Figure 1 Figures e3 and e4 ) and the Hosmer-Lemeshow test. The scaled Brier scores were similar at 70 and 72%, indicating strong overall performance. Table 3 summarizes the sensitivity, specificity, and likelihood ratios for cut points of interest. The maximal cut points with 100% sensitivity were a raw AscAo diameter of 34 mm, and a Z-score of 1.84, with respective specificities of 35% (95% CI = 29.6%-40.2%) and 67% (95% CI = 61.7%-72.2%). The optimal cut points (maximal sum of sensitivity and specificity) were a raw diameter of 42 mm and a Z-score of 2.95, with respective sensitivities of 93.5 and 91.0% and specificities of 89.2 and 91.0%.
Bland-Altman analysis indicated strong intra-rater reliability for cases and controls, with a bias of -0.3 and 0.1 mm, absolute limits of agreement of AE2.2 and AE 1.7 mm, and relative limits of agreement of AE2.2 and AE 4.8%, respectively (Data Supplement S1, Figures e5 and e6) . Inter-rater reliability as assessed by Bland-Altman analysis was slightly less robust with a bias of -0.6 mm, absolute limits of agreement of AE4.3 mm, and relative limits of agreement of AE8.7%, but revealed a strong intra-class correlation coefficient of 0.95 (95% CI = 0.93-0.97; Data Supplement S1, Figure e7 ). These findings are similar to inter-observer variations reported between cardiothoracic radiologists measuring AscAo diameters using cardiac-gated CT images. 
DISCUSSION
The objective of this study was to examine AscAo diameter thresholds, below which the probability of acute TAAD is negligible and/or exceedingly small. From an absolute diameter perspective, 100 and 93.5% of patients in this series had AscAo diameters of at least 34 and 42 mm, respectively. This is notable in comparison to a study of 4,039 asymptomatic adult patients undergoing noncontrast cardiac CT, in which the mean AscAo diameter was 33 mm and the upper limit of normal was 41 mm. 12 We found that normalizing these raw AscAo measurements for sex, age, and BSA appeared to offer improved specificity since all cases registered a Z-score > 1.84, meaning that 96.7% of a disease-free reference population would be expected to have smaller normalized AscAo measurements. 10 However, systems for generating normalized AscAo values (ideally via calculators integrated into the electronic health record) would be necessary to make their use clinical practical. It is also notable that most cases of TAAD in our study had AscAo diameters below the traditional cutoff of 55 mm for preventative aortic surgery (the median AscAo diameter among cases of TAAD was 50 mm), a finding consistent with prior registry reports. 1, 9 How might these findings be practically applied for further study and clinical use? Foremost, it should be stated that identification of moderate levels of aortic dilation (40 to 55 mm), specifically among asymptomatic patients, does not indicate an imminent risk of TAAD. While it appears from these and other observational data that some dilation of the aorta is a nearly universal necessary risk factor for TAAD, 1, 9, 22 the absolute incidence of TAAD is quite low at AscAo diameters less than 55 mm, with 5-year risk estimates of 0.1 and 0.4% for patients with diameters of 40 and 45 mm, respectively, underscoring the relative rarity of TAAD. 23, 24 Second, there is likely an acute increase in AscAo size in the setting of TAAD, meaning that the observed cutoffs in this study might be more reflective of the pathophysiology of TAAD, as opposed to intrinsic premorbid risk. 25 As such, the discriminatory capacity of the AscAo diameters as presented herein are best applied as diagnostic modifiers, rather than as screening tests for disease risk. Continuous NRI (95% CI*) 0.30 (0.13-0.47) AscAo = ascending aorta; AUC = area under receiver operating characteristic curve; IQR = interquartile range; NRI = net reclassification index. *Bootstrapped estimates using 1,000 replications drawn separately from cases and controls based on an estimated disease prevalence of 0.4 per 10,000. †p = 0.09.
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Given very low estimated testing thresholds for TAAD, 6 combined with the inherent imprecision of point estimates derived herein, this information should also not be used indiscriminately to determine which patients should undergo criterion standard testing (i.e., CT aortography, MRI, or TEE) for TAAD. However, these data could be applied (with further validation) to help modify TAAD risk estimates when those criterion standard imaging tests are either unavailable, nondiagnostic (e.g., due to inadequate contrast opacification), or contraindicated (renal failure, esophageal strictures, anaphylactic allergy, etc.). In these circumstances, two readily available alternatives (noncontrast CT and TTE) can provide accurate measures of AscAo diameter. While noncontrast CT may be the preferred option given ease of access, quick speed and minimal technical barriers, both TTE and TEE provide similarly accurate measurements of AscAo diameters compared to CT. 26, 27 TTE also has better inter-rater reliability compared to CT, even among centers of aorta excellence. 28 Additionally, TTE-derived measures of AscAo diameters have been investigated as adjuncts to the aortic dissection detection risk score. 29, 30 However, since the current study findings are solely derived from CT measurements, they should not be directly extrapolated to TTE-derived measurements without further study.
From a feasibility standpoint, it is important to note that studies of directed transthoracic cardiac ultrasound examining AscAo diameters at the point of care have demonstrated notable differences in performance between echocardiographers and clinician sonographers. Two studies examining the ability of emergency physicians to detect AscAo dilation yielded sensitivities of 77 and 79% compared to CT, whereas two studies of formal echocardiography reported sensitivities of 87 and 92%, one of which found specific signs of TAAD in up to 97% of cases. 27, [31] [32] [33] As point-of-care ultrasound technology improves with time, it is likely that imaging quality, clinician experience, and resultant test sensitivity will improve concordantly, raising the likelihood that the findings from this study could be clinically validated in the context of TTE-directed diagnostic protocols. In the meanwhile, it is important to remember that the practical use of point-of-care TTE by clinician sonographers to detect AscAo dilatation is an endeavor that has fallen short of being clinically reliable to date. 30 
LIMITATIONS
Given the retrospective nature of the study, cases were screened for inclusion using ICD codes. While we did additionally confirm the presence of acute TAAD both with confirmatory CT imaging and with a documented clinical concern for an acute process, we cannot exclude the possibility that some cases of acute TAAD were not included in the cohort. However, it seems unlikely that any missed cases due to incomplete diagnostic coding would be biased in terms of AscAo diameter. Also, while we did not reach our intended case-to-control ratio goal of 1:2 (0.5), in retrospect this was an excessive goal given our intention to maximize cut-point sensitivity, as well as the high AUC of the AscAo diameters, circumstances under which the optimal case to control ratio (for a given sample size) is actually above 1. 34 A key limitation of our data is the variability in AscAo size that occurs throughout the cardiac cycle, given that cardiac-gated CT image capture was rarely employed in this study, as is typical under emergent diagnostic circumstances.
14 Studies have reported average changes in AscAo diameters of 2 mm or 3% between end-diastole and end-systole, and guidelines thus recommend the use of CT detector-arrays with > 64 rows in conjunction with cardiac gating for imaging capture. 13, 14, 35, 36 Using echocardiography or CT, the minimal AscAo diameter is typically obtained at end-diastole and the maximal AscAo diameter is typically observed during systole, although professional guidelines recommend measurement at end-diastole, largely by precedent. 37, 38 Since a lack of cardiac gating would be expected to overestimate the size of the aorta compared to a measurements obtained at end-diastole, 36 the application of the cutoffs suggested in this study should arguably be limited to measurements obtained at end-systole to ensure maximal sensitivity for TAAD. This nuance also highlights the importance of developing standard interchangeable methodologies for obtaining AscAo diameter measurements across imaging modalities, which are as of yet unestablished. 39 Ideally, the measurements of AscAo diameters in this study would have been determined by experts in cardiothoracic radiology. However, given that our measures of intra-and inter-rater reliability are similar to those seen among expert raters in terms of percent variation, the added utility of such a design is debateable. 21 More impactful perhaps was the general unavailability of double oblique reconstructions, which can provide true anatomic perpendicular measures of the AscAo and are recommended for use in obtaining aortic measures, though not consistently used in clinical practice. 37 For this reason, our measures were taken at the level of the right main pulmonary artery, a level at which measurements obtained by standard axial cuts do not vary in diameter by more than 1 to 2 mm or 2% on average between anatomically aligned double oblique reconstructions, and thus are also within established intra-and inter-rater ranges of variation. 21, 40 Finally, while the use of the normalized measurements appeared to offer superior specificity at the 100% sensitivity cut point (67% for the normalized vs. 35% for the raw measure), this finding may be spurious, given the relative equality in AUCs between the two measures, as well as similar observed sensitivities and specificities at the optimal cut points. Also, we used a specific formula derived from echocardiographic measures in a reference population, 10 and thus the Z-score data in this study (at least in terms of absolute values) is not generalizable to other published formulas predicting AscAo size. Finally, the BSA values used to calculate the normalized measurements were derived from the electronic health record and may have been inaccurate. Accordingly, the raw cutoffs presented in this study are arguably best suited for further investigation and validation, although further research on normalized values should ideally be conducted in tandem.
CONCLUSION
Patients with type A aortic dissection appear to have uniformly enlarged ascending aorta diameters as measured by noncontrast computed tomography, whereas most patients with suspected but absent type A aortic dissection have relatively normal ascending aorta diameters. These data may be useful in adjudicating risk among patients with suspected type A aortic dissection for whom a criterion standard test is unavailable, nondiagnostic, or contraindicated. Further validation is needed prior to clinical adoption, including studies using data from alternative imaging modalities (e.g., transthoracic echocardiography).
